Aktis Oncology, Inc. Common stock (AKTS) — Cash Flow Reinvestment Rate
Aktis Oncology, Inc. Common stock (AKTS) has a Cash Flow Reinvestment Rate of 12.90x as of December 2024, reinvesting $190.40 Million (capex $2.86 Million plus investments $-187.54 Million) from operating cash flow of $14.76 Million. See Aktis Oncology, Inc. Common stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Aktis Oncology, Inc. Common stock Cash Flow Reinvestment Rate (2024–2024)
Historical reinvestment intensity for Aktis Oncology, Inc. Common stock across 1 annual periods. For the full cash flow conversion analysis, see AKTS cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Aktis Oncology, Inc. Common stock (2024–2024)
Year-by-year capital reinvestment analysis for Aktis Oncology, Inc. Common stock. See Aktis Oncology, Inc. Common stock (AKTS) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 12.90x | $190.40 Million | $14.76 Million | $2.86 Million | — |